Call us : USA : 1-631-381-2994; Europe : 44-207-097-1828
Mail us : info@creative-biolabs.com
Creative Biolabs Bispecific Antibody Blog

Menu

Skip to content
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News

Monthly Archives: February 2019

The World’s First Single-domain Antibody Drug Cablivi is Approved by FDA in the United States

February 19, 2019NewsaTTP, sdAb, Single-domain Antibodybiobsab

French pharmaceutical giant Sanofi recently announced that the US Food and Drug Administration (FDA) has approved the single-domain antibody (sdAb) drug Cablivi (caplacizumab) combined with plasma exchange and immunosuppressive therapy, for theRead More…

Categories

  • Bispecific Antibody Clinic
  • Bispecific Antibody Research
  • News

Recent Posts

  • Overview of Bispecific Antibody Drug Technology (Part II)
  • Overview of Bispecific Antibody Drug Technology (Part I)
  • Bispecific Antibodies Targeting Dual Tumor-associated Antigens
  • Difficulties and Prospects in the Research and Development of Bispecific Antibodies
  • Current Status of Research and Development of Multispecific Antibodies

Archives

  • March 2021
  • December 2020
  • October 2020
  • August 2020
  • June 2019
  • April 2019
  • March 2019
  • February 2019
  • December 2018
  • November 2018
  • October 2018

Contact Us

Address: USA - UK - Germany
Tel (USA): 1-631-381-2994
Tel (Europe): 44-207-097-1828
Email: info@creative-biolabs.com
Copyright © Creative Biolabs Bispecific Antibody Blog
Powered by WordPress , Designed and Developed by templatesnext
MENU
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News